Clinical Trial Update: Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Forodesine Hydrochloride (BCX-1777) was evaluated in a Phase 1/2 clinical trial for B-cell acute lymphoblastic leukemia. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Forodesine hydrochloride (forodesine hydrochloride)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED